<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582409</url>
  </required_header>
  <id_info>
    <org_study_id>CHSY244X2201</org_study_id>
    <secondary_id>2020-004327-17</secondary_id>
    <nct_id>NCT04582409</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation</brief_title>
  <official_title>A Randomized, Placebo-controlled, Investigator- and Participant-blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, tolerability, and&#xD;
      pharmacokinetics of HSY244 in participants with atrial fibrillation (AF), with and without&#xD;
      heart failure (HF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized and assigned to one of the following 2 treatment arms in a&#xD;
      ratio of 1:1:&#xD;
&#xD;
      Arm 1: HSY244 intravenous infusion Arm 2: Placebo intravenous infusion&#xD;
&#xD;
      The study consists of a screening period of up to 3 days and a treatment period of 5 days.&#xD;
      After confirming eligibility on Day 1 and pre-dose assessments are completed, study&#xD;
      administration will occur and participants will be monitored for cardioversion to sinus&#xD;
      rhythm. During the treatment period, participants will be evaluated for efficacy, safety,&#xD;
      tolerability, and pharmacokinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">August 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion to sinus rhythm for at least 1 minute within 90 minutes from the start of study drug administration</measure>
    <time_frame>1 day</time_frame>
    <description>Conversion to sinus rhythm will be monitored using a Holter monitoring device through 90 minutes after drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>4 days</time_frame>
    <description>The Cmax is the observed maximum plasma concentration following administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Concentration After Drug Administration (Tmax)</measure>
    <time_frame>4 days</time_frame>
    <description>Tmax is the time to reach peak or maximum concentration after drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUClast)</measure>
    <time_frame>4 days</time_frame>
    <description>AUClast is the area under the plasma concentration-time curve following drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>HSY244</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSY244 concentrate solution for injection via intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo concentrate solution for injection via intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSY244</intervention_name>
    <description>HSY244 concentrate solution for injection via intravenous infusion</description>
    <arm_group_label>HSY244</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>concentrate solution for injection via intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Hemodynamically stable men and women between 18 and 80 years of age with a clinical&#xD;
             indication for direct current cardioversion of AF&#xD;
&#xD;
          -  Current episode of AF has been ongoing for &gt;= 6 hours and =&lt; 30 days&#xD;
&#xD;
          -  Successful initiation and achievement of therapeutic levels of national guideline and&#xD;
             institution-specific anticoagulation therapy as appropriate for the duration of the AF&#xD;
             episode and risk for the participant&#xD;
&#xD;
          -  Completion of national guideline and institution-specific imaging evaluation for left&#xD;
             atrial thrombi as appropriate for the duration of AF episode and risk for the&#xD;
             participant&#xD;
&#xD;
          -  Participants must weigh at least 60 kg to participate in the study, and must have a&#xD;
             body mass index (BMI) within the range of 18 - 45 kg/m2. BMI = Body weight (kg) /&#xD;
             [Height (m)2]&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed and only&#xD;
             participants able to provide written informed consent themselves will be included in&#xD;
             this study&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Use of any class I or III anti-arrhythmic medication, or other prohibited medications,&#xD;
             within 5 half-lives before randomization, including use of amiodarone within 3 months&#xD;
             before randomization&#xD;
&#xD;
          -  History or current diagnosis of electrocardiogram (ECG) abnormalities or cardiac&#xD;
             rhythm disorders indicating significant risk of safety for participant as determined&#xD;
             by the Investigator's interpretation of the ECG findings&#xD;
&#xD;
          -  Clinically significant sinus node dysfunction and/or presence of a permanent pacemaker&#xD;
&#xD;
          -  Attempted or unsuccessful cardioversion within 2 weeks prior to randomization&#xD;
&#xD;
          -  History of 2 or more ablation procedures for AF&#xD;
&#xD;
          -  Presence of known severe mitral regurgitation and/or known severely dilated left&#xD;
             atrium&#xD;
&#xD;
          -  Pre-existing or tachycardia-induced moderate to severe cardiac dysfunction (New York&#xD;
             Heart Association class III or IV)&#xD;
&#xD;
          -  History within the preceding 3 months prior to randomization of either a: myocardial&#xD;
             infarction, unstable angina, cardiac surgery, or a percutaneous coronary intervention&#xD;
&#xD;
          -  History of confirmed stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          -  History or current diagnosis of any seizure disorder or major neurological disorder or&#xD;
             major psychiatric disorder&#xD;
&#xD;
          -  Sexually active males, including those post-vasectomy, must use a condom during sexual&#xD;
             intercourse for at least 96 hours after dosing to prevent delivery of the drug via&#xD;
             seminal fluid and should not father a child during this period&#xD;
&#xD;
          -  Women must be either of non-childbearing potential or child-bearing potential using&#xD;
             highly effective non-hormonal contraception&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>arrhythmia</keyword>
  <keyword>pharmacological cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

